Table 1.
Baseline characteristics of PLWH with NTM infection
| n (%) | |
|---|---|
| General information | |
| Total number of patients | 379 |
| Male sex | 355 (93.7%) |
| Age [years], Median (IQR) | 38.0 (30.0–50.0) |
| Smoking (current or former) | 28 (7.4%) |
| Alcoholism | 10 (2.6%) |
| Comorbidity | 113 (29.8%) |
| Opportunistic infection | 136 (35.9%) |
| Cryptococcosis | 35 (25.7%) |
| Cytomegalovirus | 28 (20.6%) |
| Digestive tract fungal infections | 23 (16.9%) |
| Pneumocystis pneumonia | 12 (8.8%) |
| Talaromyces marneffei | 11 (8.1%) |
| Kaposi’s Sarcoma | 8 (5.9%) |
| Herpes zoster | 5 (3.7%) |
| Mycobacterium tuberculosis | 4 (2.9%) |
| Salmonella infection | 3 (2.2%) |
| Pulmonary aspergillosis | 2 (1.5%) |
| Bacterial pneumonia | 2 (1.5%) |
| Cerebral toxoplasmosis | 2 (1.5%) |
| Progressive multifocal leukoencephalopathy | 1 (0.7%) |
| Clinical manifestations | |
| Fever | 236 (63.4%) |
| Cough | 164 (44.1%) |
| HIV wasting syndrome | 81 (22.8%) |
| Abdominal pain and diarrhea | 68 (18.3%) |
| Central nervous system symptoms | 48 (12.9%) |
| Rash | 43 (11.6%) |
| HIV-related indicators | |
| CD4+ T cell count [cells/μl], Median (IQR) | 23 (6.0–73.8) |
| HIV viral load [log10 copies/ml], Median (IQR) | 4.8 (1.9–5.5) |
| ART before NTM treatment | 294 (77.6%) |
| ART to anti-NTM time, Median (IQR) | 31 (4.0–127.0) |
| NTM treatment | |
| Macrolides | 280 (73.9%) |
| Levofloxacin/Moxifloxacin | 248 (65.4%) |
| Ethambutol | 317 (83.6%) |
| Rifampicin/Rifabutin | 248 (65.4%) |
| Linezolid | 23 (6.1%) |
PLWH people living with HIV, NTM nontuberculous mycobacteria, IQR interquartile range, HIV human immunodeficiency virus, ART antiretroviral therapy